Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511942 | PMC |
| http://dx.doi.org/10.3904/kjim.2016.219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The kidney reabsorption-related magnesium depletion score is associated with cardiovascular disease and longitudinal mortality in diabetic kidney disease patients.
Diabetol Metab Syndr
January 2025
Department of Urology, Ningbo Mingzhou Hospital, Zhejiang, China.
Background: The kidney reabsorption is essential for maintaining magnesium homeostasis. This study aims to explore the relationship between kidney reabsorption-related magnesium depletion score (MDS) and the occurrence of cardiovascular disease (CVD) and prognosis in diabetic disease kidney (DKD) patients.
Methods: We included 3199 DKD patients from the National Health and Nutrition Examination Survey (NHANES) database, including 1072 CVD patients.
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges.
Cardiovasc Diabetol
January 2025
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential.
View Article and Find Full Text PDFDefective Slc7a7 transport reduces erythropoietin compromising erythropoiesis.
Mol Med
January 2025
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Background: Lysinuric protein intolerance is a rare autosomal disorder caused by mutations in the Slc7a7 gene that lead to impaired transport of neutral and basic amino acids. The gold standard treatment for lysinuric protein intolerance involves a low-protein diet and citrulline supplementation. While this approach partially improves cationic amino acid plasma levels and alleviates some symptoms, long-term treatment is suggested to be detrimental and may lead to life-threatening complications characterized by a wide range of hematological and immunological abnormalities.
View Article and Find Full Text PDFTrends in incidence, prevalence, and mortality of non-communicable diseases in Iraq (2003-2021).
BMC Public Health
January 2025
Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Background: Non-communicable diseases (NCDs) have become a major public health concern in Iraq, playing a significant role in the country's morbidity and mortality rates. To offer a thorough overview of the patterns and the overall impact of NCDs on public health, this study aims to map the trends in the incidence, prevalence, and mortality rates of NCDs in Iraq between 2003 and 2021.
Methods: Data from the Global Burden of Disease (GBD) Study 2021 were utilized.
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion.
Nat Biotechnol
January 2025
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Therapeutic efficacy and safety of adeno-associated virus (AAV) liver gene therapy depend on capsid choice. To predict AAV capsid performance under near-clinical conditions, we established side-by-side comparison at single-cell resolution in human livers maintained by normothermic machine perfusion. AAV-LK03 transduced hepatocytes much more efficiently and specifically than AAV5, AAV8 and AAV6, which are most commonly used clinically, and AAV-NP59, which is better at transducing human hepatocytes engrafted in immune-deficient mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!